Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes

Mycoses

Volumn 51, Issue 2, 2008, Pages 147-154

  Simitsopoulou, Maria ^a   Roilides, Emmanuel ^a,b   Maloukou, Avgi ^a   Gil Lamaignere, Cristina ^a   Walsh, Thomas J ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Lipid formulations of amphotericin B; Polymorphonuclear leucocytes; Triazoles; Zygomycetes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABSIDIA; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FUNGAL VIRULENCE; FUNGUS; FUNGUS HYPHAE; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; SPECIES COMPARISON; ZYGOMYCETES;

ABSIDIA; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; HYPHAE; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; NEUTROPHILS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PYRIMIDINES; RHIZOPUS; TRIAZOLES;

ABSIDIA CORYMBIFERA; FUNGI; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; ZYGOMYCETES;

EID: 38849110846     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01457.x     Document Type: Article

References (46)

1. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004 89:207 14.
2. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003 16:607 12.
3. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004 39:588 90.
4. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002 16:895 914.
5. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004 10 (Suppl 1 31 47.
6. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000 13:236 301.
7. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005 41:634 53.
8. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005 41:60 66.
9. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998 42:741 5.
10. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998 41:309 19.
11. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002 46:1581 2.
12. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003 47:3647 50.
13. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002 49 (Suppl 1 31 36.
14. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997 24:192 6.
15. Parkyn T, McNinch AW, Riordan T, Mott M. Zygomycosis in relapsed acute leukaemia. J Infect 2000 41:265 8.
16. Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003 4:2099 110.
17. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26:1383 96.
18. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003 20:201 6.
19. Bakshi NA, Volk EE. Pulmonary mucormycosis diagnosed by fine needle aspiration cytology. A case report. Acta Cytol 2001 45:411 14.
20. Demirag A, Elkhammas EA, Henry ML, et al. Pulmonary Rhizopus infection in a diabetic renal transplant recipient. Clin Transplant 2000 14:8 10.
21. Thami GP, Kaur S, Bawa AS, Chander J, Mohan H, Bedi MS. Post-surgical zygomycotic necrotizing subcutaneous infection caused by Absidia corymbifera. Clin Exp Dermatol 2003 28:251 3.
22. Morales-Aguirre JJ, Aguero-Echeverria WM, Ornelas-Carsolio ME, Resendiz-Sanchez J, Gomez-Barreto D, Cashat-Cruz M. Successful treatment of a primary cutaneous zygomycosis caused by Absidia corymbifera in a premature newborn. Pediatr Infect Dis J 2004 23:470 2.
23. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982 38:487 95.
24. Diamond RD, Haudenschild CC, Erickson NF III. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982 38:292 7.
25. Diamond RD, Krzesicki R, Epstein B, Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978 91:313 28.
26. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005 191:1180 7.
27. Keating GM. Posaconazole. Drugs 2005 65:1553 67 discussion 68 69.
28. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 50:126 33.
29. Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997 35:139 43.
30. Meshulam T, Levitz SM, Christin L, Diamond RD. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2- methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT). J Infect Dis 1995 172:1153 6.
31. Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002 46:1974 6.
32. Gil-Lamaignere C, Roilides E, Maloukou A, Georgopoulou I, Petrikkos G, Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002 50:1027 30.
33. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002 49 (Suppl 1 21 30.
34. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002 49 (Suppl 1 7 10.
35. Trouet A. The amphotericin B lipid complex or Abelcet: its Belgian connection, its mode of action and specificity: a review. Acta Clin Belg 2002 57:53 57.
36. Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998 42:767 71.
37. Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000 38 (Suppl 1 335 47.
38. Ghannoum MA, Okogbule-Wonodi I, Bhat N, Sanati H. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J Chemother 1999 11:34 39.
39. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998 42:2299 303.
40. Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998 42:907 10.
41. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002 46:2234 7.
42. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 350:950 2.
43. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004 39:743 6.
44. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 191:1350 60.
45. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or 'immuno-fairy tales'? Clin Microbiol Rev 2000 13:615 50.
46. Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005 55:214 22.